H LUNDBECK A/S Stock News

Lundbeck's new CEO has laid out a plan to maximize the value of the company's current portfolio, reorganize R&D, and deploy capital towards growth-sustaining M&A. The company aims to maximize the valu

DEERFIELD, Ill.--(BUSINESS WIRE)--Lundbeck to Present Broad Range of Data on Migraine and Brain Health at 75th Annual Meeting of the American Academy of Neurology

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., and H. Lundbeck A/S (Lundbeck) today announce that new Phase 3 data for brexpiprazole w

H Lundbeck AS (HLUYY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre

DUBLIN--(BUSINESS WIRE)--The "Research Report on China''s Escitalopram Market, 2021-2025" report has been added to ResearchAndMarkets.com''s offering. According to the publisher''s market research, as a result of the impact of COVID-19 and the decreasing average price, the sales value of China''s escitalopram market in 2020 declined to approximately CNY329 million (USD50.6 million), with a CAGR of about -1.9% from 2016 to 2020. Since H. Lundbeck A/S''s Lexapro is more expensive than generic drugs in

H. Lundbeck A/S (HLUKF) CEO Deborah Dunsire on Q4 2021 Results - Earnings Call Transcript

H. Lundbeck A/S press release (HLUKF): FY GAAP EPS of $6.63.Revenue of $16.3M (-7.8% Y/Y) misses by $2.49B.

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.

H. Lundbeck A/S (OTCMKTS:HLUYY) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, Zacks.com reports. According to Zacks, “H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals across the world. […]

H. Lundbeck A/S (OTCMKTS:HLUYY) has been given a consensus recommendation of Hold by the eight analysts that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1 year price []

This Alzheimer''s Pipeline Drugs market research demonstrates realistic market judgments. Knowing this enables key stakeholders to make better business decisions, such as bringing the proper products to market. It discusses precise customer insight in order to develop technical solutions that

VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Pure Extracts Technologies Corp . (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (Pure Extracts or the Company), a plant-based extraction company focused on cannabis, hemp, functional mushrooms and the rapidly emerging psychedelic sector, is pleased to announce that its wholly owned subsidiary, Pure Extracts Manufacturing Corp., has shipped another order of vape carts via its distribution partner, Abba Medix, to the British Columbia Liquor Distribution Branch (LDB), the sole wholesale distributor of non-medical cannabis in the province.

H. Lundbeck A/S (OTCMKTS:HLUYY) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $24.88 and last traded at $25.17, with a volume of 1832 shares. The stock had previously closed at $25.77. Several equities analysts have recently issued reports on HLUYY shares. Zacks Investment Research upgraded H. []

Berenberg Bank assumed coverage on shares of H. Lundbeck A/S (OTCMKTS:HLUYY) in a report published on Wednesday morning, The Fly reports. The brokerage issued a buy rating on the stock. Several other equities research analysts also recently weighed in on HLUYY. Deutsche Bank Aktiengesellschaft reaffirmed a sell rating on shares of H. Lundbeck A/S in []